Now Patient

nowpatient.com

Now Patient is a new health app for NHS patients, created by leading telehealth organisation Now Healthcare Group. Available for iOS and Android devices, Now Patient provides FREE repeat medicines delivered to your home and FREE access to GPs and nurses via smartphone-based video consultation.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMACY MARKET

IA COMMEMORATES 50 YEARS OF INNOVATION WITH LAUNCH OF NEW PHARMACY SOLUTIONS AT NACDS TOTAL STORE EXPO

iA | August 26, 2022

news image

iA, a leading provider of pharmacy fulfillment and automation solutions, is celebrating 50 years of innovation at NACDS Total Store Expo. With a commitment to its heritage, iA’s mission has never wavered from streamlining operational processes through advancing technology. Today, iA continues to drive pharmacy industry innovations. From safe and accurate filling of prescriptions through the use of modern robotics, to production control software enhanced by warehouse manageme...

Read More

PHARMA TECH

SILVERBACK THERAPEUTICS AND ARS PHARMACEUTICALS ANNOUNCE MERGER

Silverback Therapeutics and ARS Pharmaceuticals | July 22, 2022

news image

Silverback Therapeutics, Inc. and ARS Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. The combined company is expected to have approximately $265M in cash, cash ...

Read More

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

news image

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More

BUSINESS INSIGHTS

SPOTLIGHT THERAPEUTICS APPOINTS VISIONARY GLOBAL PHARMA DRUG DEVELOPER ANTOINE YVER, M.D., M.SC. AS FIRST INDEPENDENT BOARD MEMBER

Spotlight Therapeutics | July 18, 2022

news image

Spotlight Therapeutics, Inc. a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE platform and advance lead therapeutic candidates towards the c...

Read More
news image

PHARMACY MARKET

IA COMMEMORATES 50 YEARS OF INNOVATION WITH LAUNCH OF NEW PHARMACY SOLUTIONS AT NACDS TOTAL STORE EXPO

iA | August 26, 2022

iA, a leading provider of pharmacy fulfillment and automation solutions, is celebrating 50 years of innovation at NACDS Total Store Expo. With a commitment to its heritage, iA’s mission has never wavered from streamlining operational processes through advancing technology. Today, iA continues to drive pharmacy industry innovations. From safe and accurate filling of prescriptions through the use of modern robotics, to production control software enhanced by warehouse manageme...

Read More
news image

PHARMA TECH

SILVERBACK THERAPEUTICS AND ARS PHARMACEUTICALS ANNOUNCE MERGER

Silverback Therapeutics and ARS Pharmaceuticals | July 22, 2022

Silverback Therapeutics, Inc. and ARS Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which ARS will merge with Silverback in an all-stock transaction. The combined company will focus on the potential regulatory approval and commercialization of neffy, ARS’s investigational epinephrine nasal spray for the treatment of Type I allergic reactions including anaphylaxis. The combined company is expected to have approximately $265M in cash, cash ...

Read More
news image

MAYNE PHARMA ANNOUNCES FDA FILING ACCEPTANCE OF NEW DRUG APPLICATION FOR E4/DRSP IN THE US

Mayne Pharma, Mithra | June 24, 2020

Mayne Pharma Group Limited (ASX: MYX) is pleased to announce the New Drug Application (NDA) for E4/DRSP to prevent pregnancy has been accepted for review by the US Food and Drug Administration (FDA). The FDA is expected to complete its review in the first half of calendar 2021. Developed by Mithra Pharmaceuticals SA (Mithra), E4/DRSP is a novel combined oral contraceptive pill containing 15 mg estetrol (E4) and 3 mg drospirenone (DRSP). E4 is a naturally occurring estrogen that is...

Read More
news image

BUSINESS INSIGHTS

SPOTLIGHT THERAPEUTICS APPOINTS VISIONARY GLOBAL PHARMA DRUG DEVELOPER ANTOINE YVER, M.D., M.SC. AS FIRST INDEPENDENT BOARD MEMBER

Spotlight Therapeutics | July 18, 2022

Spotlight Therapeutics, Inc. a biotechnology company applying new insights to develop cell-targeted in vivo CRISPR gene editing biologics, announced the appointment of Antoine Yver, M.D., M.Sc. to the Spotlight Board of Directors. Trained as an oncologist and immunologist, Dr. Yver’s extensive industry experience and perceptive acumen will be extremely valuable as Spotlight continues to strengthen its highly differentiated TAGE platform and advance lead therapeutic candidates towards the c...

Read More